Deutsche Bank downgrades 10X Genomics stock to ‘Hold’ on market pressures By Investing.com

On Wednesday, Deutsche Bank adjusted its stance on 10X Genomics (NASDAQ: TXG), shifting the stock rating from Buy to Hold and significantly lowering the price target to $25.00 from the previous $55.00.

The revision comes amid concerns over increasing market competition, which is believed to be impacting the demand for the company’s leading single-cell analysis platform.

The bank’s analysis suggests that the growth of 10X Genomics’ Chromium platform could be hampered in the short term, facing more significant volume declines and pricing pressure than the company’s management currently anticipates. This is expected to continue the trend of margin erosion for 10X Genomics.

The competitive landscape for 10X Genomics has become more challenging with Illumina (NASDAQ:)’s recent acquisition of Fluent (NASDAQ:), a private single-cell analysis company. This move is seen as a direct threat to 10X Genomics, particularly as Illumina, a major player in the next-generation sequencing (NGS) market, may leverage its existing instruments to create bundled product offerings. Such strategies could potentially disrupt the established market dynamics.

Illumina’s strategic maneuvers come after it was required to divest GRAIL, a company focused on early cancer detection. The acquisition of Fluent is part of Illumina’s efforts to explore new market opportunities and strengthen its position in the single-cell analysis segment.

The downgraded outlook for 10X Genomics reflects the analyst’s view that the company may struggle to maintain its previously unchallenged market position due to these evolving industry conditions. The new price target of $25.00 represents a significant reduction, indicating a more conservative expectation of the company’s stock performance in the near future.

In other recent news, 10x Genomics (NASDAQ:) welcomed Alan V. Mateo to its Board of Directors, bringing his extensive commercial leadership experience in the life science industry. The company also started shipping its latest product, the Xenium Prime 5K Pan-Tissue and Pathways panel, designed to significantly enhance gene analysis.

In corporate matters, Kimberly J. Popovits was elected as a Class II director, and Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024.

ARK ETFs, managed by Cathie Wood, recently made significant investments in 10x Genomics, Roku (NASDAQ:) Inc., and PagerDuty (NYSE:) Inc. while reducing positions in Ginkgo Bioworks Holdings (NYSE:) Inc., Coinbase (NASDAQ:) Global Inc., and Teladoc (NYSE:) Health Inc. These trades reflect ARK’s strategic direction and conviction in various market sectors.

Jefferies initiated coverage on 10x Genomics with a Hold rating, indicating their perspective on the company’s future performance. As these developments unfold, investors and market observers will likely continue to monitor the company’s strategic moves and market performance.

InvestingPro Insights

In light of Deutsche Bank’s recent rating change for 10X Genomics, current metrics from InvestingPro provide additional context for investors considering the stock. With a market capitalization of $2.18 billion, 10X Genomics is navigating a challenging market environment. The company’s revenue growth remains positive, with a 16.64% increase over the last twelve months as of Q1 2024, and a quarterly revenue growth of 5.01% in Q1 2024, showcasing its ability to expand despite market headwinds.

InvestingPro Tips highlight that 10X Genomics holds more cash than debt on its balance sheet and that its liquid assets exceed short-term obligations, suggesting a degree of financial stability. However, analysts are concerned as the stock is currently in oversold territory and has experienced significant price declines over the last three months. Moreover, the company is not expected to be profitable this year, and two analysts have revised their earnings downwards for the upcoming period, indicating potential challenges ahead.

For investors seeking a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into 10X Genomics’ performance and outlook. Utilizing the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to access these valuable tips and make more informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.